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ABSTRACT
Introduction: Few randomized controlled trials
have compared new treatments for metastatic
melanoma. We sought to examine the relative
treatment effect of talimogene laherparepvec
compared with ipilimumab and vemurafenib.
Methods: A systematic literature review of
treatments for metastatic melanoma was
undertaken but a valid network of evidence
could not be established because of a lack of
comparative data or studies with sufficient
common comparators. A conventional
adjusted indirect treatment comparison via
network meta-analysis was, therefore, not
feasible. Instead, a meta-analysis of absolute
efficacy was undertaken, adjusting overall
survival (OS) data for differences in prognostic
factors between studies using a published
algorithm.
Results: Four trials were included in the final
indirect treatment comparison: two of
ipilimumab, one of vemurafenib, and one of
talimogene laherparepvec. Median OS for
ipilimumab and vemurafenib increased
significantly when adjustment was applied,
demonstrating that variation in disease and
patient characteristics was biasing OS estimates;
adjusting for this made the survival data more
comparable. For both ipilimumab and
vemurafenib, the adjustments improved
Kaplan–Meier OS curves; the observed
talimogene laherparepvec OS curve remained
above the adjusted OS curves for ipilimumab
and vemurafenib, showing that long-term
survival could differ from the observed
medians.
Conclusion: Even with limited data,
talimogene laherparepvec, ipilimumab, and
vemurafenib could be compared following
adjustments, thereby providing a more reliable
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understanding of the relative effect of treatment
on survival in a more comparable patient
population. The results of this analysis suggest
that OS with talimogene laherparepvec is at
least as good as with ipilimumab and
vemurafenib and improvement was more
pronounced in patients with no bone, brain,







Melanoma is a rare but serious form of skin
cancer that can rapidly infiltrate the deep,
vascular skin layers and often metastasizes
very early. Data from real-world clinical
practice consistently show that survival among
patients with metastatic melanoma differs
greatly by stage of disease [1]. In a study of
1682 patients with metastatic melanoma from
the Surveillance, Epidemiology, and End Results
(SEER) database [2], patients with unresectable,
non-visceral disease (stage IIIB or IIIC or IV
M1a) had a median overall survival (OS) of
22–24 months, whereas those with visceral
disease (stage IV M1b or IV M1c) had a median
OS of 5–11 months.
Until 2011, the only systemic therapies for
metastatic melanoma were conventional
agents, such as dacarbazine, fotemustine, and
interleukin-2 [3, 4], that did not show clinically
meaningful improvements in OS. Recently
licensed agents include ipilimumab,
vemurafenib, dabrafenib, trametinib,
pembrolizumab, and nivolumab, which have
all been approved by the US Food and Drug
Administration (FDA) and the European
Medicines Agency (EMA). Recent treatment
guidelines issued by the European Society for
Medical Oncology (ESMO) discuss these new
therapeutic strategies, stating that
recommendations for first-line treatment of
metastatic disease are under debate [5]. For
BRAF-mutated melanomas, combination
treatment with BRAF/MEK inhibitors is a
recommended approach. For patients with
BRAF-wild-type disease, the guidelines
highlight ipilimumab as a standard first-line
choice based on long-term survival benefit, but
state anti-PD1 therapy is currently preferred,
based on very recent trial results comparing
pembrolizumab with ipilimumab. Anti-PD1
therapies are also recommended as a
second-line treatment, after ipilimumab failure
as well as for patients with other BRAF
mutations.
Ipilimumab, a fully human, IgG1
monoclonal antibody, blocks cytotoxic T
lymphocyte-associated antigen 4 (CTLA-4), a
negative regulator of T cells, and thereby
augments T cell activation and proliferation
[24]; whereas vemurafenib is a potent inhibitor
of mutated BRAF and has marked antitumor
effects against melanoma cell lines with the
BRAF V600E mutation but not against cells with
wild-type BRAF [26].
The most recently approved therapy for
melanoma is talimogene laherparepvec, a
novel first-in-class oncolytic immunotherapy
designed to selectively replicate within tumors
and produce granulocyte macrophage
colony-stimulating factor (GM-CSF) to
enhance systemic antitumor immune
responses. First, talimogene laherparepvec
directly attacks cancer cells in the injected
tumors, and second, it helps the immune
system find and kill cancer cells throughout
the body while leaving healthy cells
undamaged [6]. Talimogene laherparepvec has
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been assessed in a Phase 3 randomized trial
(OPTiM; ClinicalTrials.gov identifier:
NCT00769704) versus GM-CSF in patients
with unresectable stage IIIB/C or IV melanoma.
In the treatment of metastatic melanoma,
there is a lack of randomized, controlled, active
comparator trials to date that would help to
compare new treatments; as shown by the
recent ESMO guidelines, the treatment
pathway for patients at different disease stages
remains unclear even as it evolves. Currently,
ipilimumab and vemurafenib, being the first
newer therapies to market, are the most widely
used newer agents. Given that indirect
treatment comparisons for newer therapies are
increasingly a requirement for health
technology assessment (HTA) agencies, the
aim of this study was to examine the relative
treatment effect of talimogene laherparepvec




Relevant trials were identified through a
systematic review conducted in September
2015 of English-language studies, published
since January 1990, on the efficacy and safety
of treatments for metastatic melanoma. All
trials were subject to a quality assessment, to
identify the appropriate highest quality trials
for inclusion. The review followed Cochrane
and Preferred Reporting Items for Systematic
Reviews and Meta-Analysis (PRISMA) guidelines
and was conducted in accordance with the key
HTA agencies’ requirements for identifying
evidence. Inclusion and exclusion criteria for
the studies are presented in Table 1. The
following databases were searched: MEDLINE,
including MEDLINE In-Process Citations and
Daily Update (PubMed) (OvidSP); Embase
(OvidSP); Cochrane Library, including
Cochrane Database of Systematic Reviews
(CDSR), Database of Abstracts of Reviews of
Effects (DARE); Cochrane Central Register of
Controlled Trials (CENTRAL), HTA Database
and NHS Economic Evaluation Database
(NHSEED). Abstracts from the following
conferences were also searched to identify
relevant studies: American Society of Clinical
Oncology (ASCO); ESMO; International Society
for Pharmacoeconomics and Outcomes
Research (ISPOR; European and international
conferences); European Association of Dermato
Oncology (EADO); European Cancer Congress
(ECC).
Data from each study’s comparator arm were
extracted, including study design, patient
characteristics, treatment (including dose,
duration), and results on primary and
secondary endpoints, and safety endpoints or
outcomes reported. Studies with a low risk of
bias were identified using the Grades of
Recommendation, Assessment, Development
and Evaluation (GRADE) criteria [8].
Establishing the Feasibility of a Valid
Network Meta-Analysis
Based on the findings from the systematic
literature review, the feasibility of establishing
a valid network meta-analysis of talimogene
laherparepvec compared with ipilimumab and
vemurafenib was explored using a process
established and published by Cope et al. [9]. A
valid network of evidence could not be
established according to the Cope algorithm
because of a lack of sufficient comparative,
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head-to-head data and of studies with sufficient
common comparators such as dacarbazine, the
glycoprotein 100 peptide vaccine (gp100), and
GM-CSF. In addition, there were issues around
the exchangeability of patient populations
across the trials. Therefore, an alternative
method was used to inform the indirect
comparisons [10]. Specifically, a meta-analysis
of absolute efficacy was undertaken, controlling
for known prognostic differences between
studies, which allowed for OS over time for
each treatment to be compared. The
methodology for this analysis is described below.
Alternative Approaches to Indirect
Treatment Comparison
Alternative approaches to indirect treatment
comparison include simulated treatment
comparison and matching-adjusted indirect
comparison [11, 12]. Simulated treatment
comparison is an approach in which detailed
predictive equations are constructed to
characterize a single index trial for which
individual patient-level data are available.
Equations include enrollment, randomization,
and follow-up. External baseline data from
Table 1 Inclusion and exclusion criteria for the systematic review
Inclusion criteria Exclusion criteria
Studies that evaluate the efﬁcacy or safety of the treatments
of interest for the target indication; mixed-line studies are
permitted
In vitro studies, studies in animals,
or other preclinical studies
Studies reporting any of the efﬁcacy and
safety endpoints of interest
Publications that are duplicates, editorials, letters, case
reports, commentaries, interview-based research, legal cases,
newspaper articles, debates, general or independent central
reviews, opinions, protocols, workshops, assay studies,
cytogenetic studies, surgical studies, or educational material
for patients
Observational, retrospective, or prospective,
randomized or non-randomized Phase 1–4 studies, or
systematic reviews, meta-analyses, or pooled analyses
Studies that do not include the treatments of interest
Studies in humans only Studies of patients with cancer other than advanced or
metastatic melanoma
Studies conducted in any country Studies that use an alternative route of administration (e.g.,
isolated limb perfusion)
Studies on the prevention or detection of melanoma
Studies of potential biomarkers or analyses of genes as
predictors of response, where those studies to not report
any of the efﬁcacy and safety endpoints of interest
Studies of patients with non-cutaneous melanoma (e.g.,
uveal/ocular melanoma)
Studies with less than 30 patients
Studies that are not published in English
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other studies can then be used to simulate those
patients’ experience and outcomes according to
the index trial. In matching-adjusted indirect
comparison, the index trial for which individual
patient-level data are available is reweighted
using propensity score-type approaches, so that
it matches the characteristics of another study.
Neither of these approaches were considered
feasible for this analysis due to the complexity
of the prognostic information, combined with
the heterogeneity in patient and trial
characteristics, including need to consider
disease stage, age, gender, visceral disease,
brain metastases, lactate dehydrogenase (LDH)
levels, in addition to any other patient or study
characteristics. In the case of simulated
treatment comparison there were not
sufficient data for the required equations; for
matching-adjusted indirect comparison, there
was also a limitation in the matching across
many prognostic factors, and the need to match
to several studies.
For this analysis, a treatment-specific
meta-analysis of absolute treatment effect was
undertaken, which involved analysis of
independent data on OS for talimogene
laherparepvec, ipilimumab, and vemurafenib
in each published study, but separate analyses
of each drug at a time. No attempt was made at
network meta-analysis, following the
assessment using the Cope framework.
However, the outcomes of each relevant
treatment arm in the studies used were
adjusted for heterogeneity in prognostic
factors (i.e., external data were adjusted
accordingly to their baseline characteristics),
to be comparable to the OPTiM trial.
Adjustments were made using a published
algorithm [13, 14].
Compared with the OPTiM trial, trials
including ipilimumab and vemurafenib had
higher percentages of patients with
stage IV M1b/c melanoma, who have a greater
mortality risk than patients with stage III
melanoma (Table 2). Patients also varied in
terms of other baseline characteristics,
including gender, Eastern Cooperative
Oncology Group (ECOG) performance status,
presence of visceral metastases, presence of
brain metastases, and LDH levels. Therefore,
adjustment was needed to permit
comparability of these factors with those of
the OPTiM trial.
The adjustment of survival for differences in
baseline characteristics was based upon a
predictive model for survival that was
developed by Korn et al. using pooled data
from 2100 patients with metastatic melanoma
treated with variety of regimens from 42 trials
conducted between 1975 and 2005 [13]. This is
valuable in this instance as the Korn model is
founded on a larger data set than the OPTiM
trial would represent, and broader in terms of
the baseline characteristics, so that it should be
less prone to bias. The Korn model
demonstrated that four factors are associated
with OS: gender, ECOG performance status,
presence of visceral metastases, and presence of
brain metastases. In 2014, a five-factor model
was used in the National Institute for Health
and Care Excellence (NICE) technology
appraisal of ipilimumab for previously
untreated advanced melanoma (NICE TA 319;
[14]), in which the original Korn model was
modified to include LDH level as the fifth factor.
The modified Korn model was accepted by NICE
and was used in this study.
Survival was adjusted using a hazard ratio
(HR) as the modifier; that is, an HR was used
that reflected the impact of the difference in
patient characteristics between a given trial and
the OPTiM trial. For example, a trial including
more patients with better ECOG performance
status, and more patients without visceral
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disease, would exhibit higher rates of survival
even without treatment; therefore, survival in
this trial would have to be adjusted downwards
so that each trial’s baseline survival better
matched baseline survival in the OPTiM trial,
and it is this effect that the Korn algorithm
achieves.
In the adjustment used, the trial-specific HR
was estimated by applying the modified Korn
model from NICE TA 319 [14], where X is the
proportion of each sample satisfying the
condition (e.g., XGender¼Female is the proportion
of females).
log HRð Þ ¼ 0:154 XGender¼Female  0:400 XECOG¼0
 0:285 XVisceral¼NO  0:306 XBrain¼NO
 0:782 XLDH¼Normal
In the equation, all variables represent a
better prognosis: if more patients in a trial are
female, more patients have ECOG status 0,
more patients have non-visceral melanoma,
more patients do not have brain metastases,
and/or more patients have normal LDH levels,
prognosis (i.e., survival) improves, and the HR is
lower. The ratio of the HR for a given trial and
the HR for the OPTiM trial becomes the





Table 2 Summary of randomized controlled Phase 3 trials included in the indirect treatment comparison, and patient

















































Unresectable, stage IIIC or IV,
positive for the BRAF
V600E mutation
Female (%) 41 44 41 39 41
ECOG 0
(%)
71 74 53 71 68
Normal
LDH (%)
90 94 61 63 58
No visceral
disease (%)




99 100 89 99 100
ECOG Eastern Cooperative Oncology Group performance status, LDH Lactate dehydrogenase, NICE National Institute
for Health and Care Excellence
a In the Bristol-Myers Squibb Pharmaceuticals Ltd. NICE submission [25], a derived ﬁrst-line, 3 mg/kg overall survival for
ipilimumab was accepted by NICE; these derived data are included in this analysis
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Implicit in this is that each of TTRIAL and
TTVEC are relative to the worst prognosis, when
all of the factors in the equation equal zero and
the adjusted HR equals 1.
Kaplan–Meier (KM) data were simulated at
each time point for TTRIAL, assuming it had the
patient population of TTVEC, which was







If a drug was studied in more than one trial
included in the analysis, the data from each trial
were combined so that all survival data on that
drug were included in the comparison. To do
this, OS data were adjusted using the modified
Korn model and were then pooled across studies
using the Mantel–Haenszel method [15, 16], a
fixed-effect model primarily for dichotomous
outcomes that can be implemented in modeling
survival counts by transformation of the
survival data into hazards, or risks, period by
period.
The procedure for this involves two stages:
first, producing data containing events and
non-events such that odds can be calculated;
these data were then combined across studies to
produce a pooled survival estimate. The data
were not combined automatically on the basis
of the single curve for survival; rather, the
Mantel–Haenszel method combines the rates of
death and censoring, across all studies, at each
time point, and the Mantel–Haenszel survival
curve is calculated from the resultant data.
Detailed procedures/steps involved are as
follows:
1. Each study’s KM data (unadjusted and
adjusted) were broken out using the
Parmar algorithm [17, 18], to produce
estimates, for each time period (in our
analysis this was 1 month), of the number
of patients at risk, the number of events
(i.e., death or progression, depending upon
whether OS data were being analyzed) and
the number of censored data points.
2. In each time interval, the data were pooled
using the Mantel–Haenszel method, which
is as follows:
(a) Pooled proportion of deaths in time
interval (sum of proportions across
included studies for each time point).
(b) Pooled proportion of patients alive
through time interval (sum of
proportions across included studies
for each time point).
(c) Mantel–Haenszel odds of dying in time
interval (a/b).
(d) Estimated probability of death in the
time interval (c/1 ? c).
(e) Estimated cumulative probability of
surviving to the end of that time
interval [probability of surviving to
end of previous time
interval 9 (1 - d)].
3. Finally, the pooled survival curve S(t) was
created from E. In this method, confidence




A subgroup indirect treatment comparison was
also analyzed, comprising patients with no
bone, brain, lung, or other visceral metastases
(stage IIIB–IV M1a disease). For this subgroup
analysis, the same methods outlined in the
previous section were used.
Extracting Survival Data for Analysis
KM curves were extracted and digitized with
DigitizeIt version 2.0.3 for studies selected in
the systematic review [19]. The digitized dataset
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of each arm of each trial included the survival
probability at consecutive half-month intervals.
To establish the quality of the digitization
outputs, median survival was determined for
each of the digitized curves and compared with
the median survival published in each study.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
RESULTS
Systematic Review and Trials Included
in the Indirect Treatment Comparison
The systematic review PRISMA chart is provided
in the online supplementary material.
Randomized controlled trials (RCTs) were
included in the meta-analysis if they were
phase III trials, published since 2010, reported
an OS curve and key baseline patient
characteristics, and studied a licensed
monotherapy agent and dose to treat patients
with metastatic melanoma. These selection
criteria were chosen to reflect the introduction
of recent melanoma treatments (ipilimumab
and vemurafenib), for which clinical trial
publications are available only from 2010.
Among the RCTs identified, four met the
inclusion criteria and were included in the
final indirect treatment comparisons: two for
ipilimumab, one for vemurafenib, and one for
talimogene laherparepvec (Table 2).
Table 2 highlights the differences between
trials in terms of line of therapy, ECOG
performance status, LDH status, presence of
visceral disease, and presence of brain
metastases. Based on these factors, in general,
patients enrolled in the OPTiM trial appeared to
have a better prognosis than other study
populations. The ipilimumab RCT in
previously untreated patients studied the
combination of ipilimumab and dacarbazine at
10 mg/kg and ipilimumab is licensed for only
monotherapy at 3 mg/kg. However, an OS curve
was derived for ipilimumab monotherapy at
3 mg/kg for this study population in the NICE
appraisal for ipilimumab in previously
untreated disease. The derived OS curve was
used in this study.
Overall Survival: All Patients
The prognostic patient characteristics used in
the adjustments for each trial are presented in
Table 2: gender, ECOG performance status,
presence of visceral metastases, presence of
brain metastases, and LDH levels. Since there
are two RCTs for ipilimumab, OS adjustment
was done for each individual trial, then the
adjusted OS data were pooled across the two
trials using the Mantel–Haenszel method [15,
16]. Data for talimogene laherparepvec and
vemurafenib were not required to be pooled,
being comprised of only a single clinical trial
each. Estimated HR for death based on the
modified Korn model and adjustment factors
are presented in Table 3.
Table 3 shows that adjustment factors ranged
between 0.53 and 0.72 and were more closely
clustered within each of the two patient
populations (overall and subgroup); however,
the results do suggest that adjustment using the
modified Korn model had a material impact.
Unadjusted and adjusted median OS for each
comparator are presented in Table 4. Adjusted
median OS significantly increased compared to
unadjusted median OS. This reflects the starting
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point of this analysis: that variation in disease
and patient characteristics were biasing survival
estimates, and by adjusting for this the survival
data are now more comparable.
Unadjusted OS curves for ipilimumab and
vemurafenib and the observed OS curve for
talimogene laherparepvec are presented in
Fig. 1, and unadjusted and adjusted OS curves
for ipilimumab and vemurafenib are presented
in Figs. 2 and 3, respectively.
For both ipilimumab and vemurafenib, the
adjustments improved survival along the entire
survival curve (i.e., the entire OS curves shifted
upward). The observed talimogene
laherparepvec OS curve remained above the
adjusted OS curves for ipilimumab and
vemurafenib, based on a combination of
gender, ECOG status, visceral and brain
metastases, and LDH level. The figures also
show difference in long-term survival, even
after adjustment. As with the results in
Table 4, the adjustment has increased survival
for ipilimumab and vemurafenib in all cases.
Overall Survival: Patients with no Visceral
Metastases (Stage IIIB–IV M1a Disease)
For the subgroup analysis of patients with no
bone, brain, lung or other visceral metastases
(stage IIIB–IV M1a disease), unadjusted and
adjusted median OS values for each comparator
are presented in Table 4. A consistently higher
adjustment for patients with no bone, brain,
lung, or other visceral metastases (stage IIIB–IV
Table 3 Overall survival curve adjustment: HR and adjustment factor for all patients and early-stage subgroup analysis







MDX0101-20 (ipilimumab, previously treated) [23] 0.35 0.22 0.64
CA184-024 (ipilimumab, previously untreated) [24, 25] 0.31 0.22 0.72
BRIM-3 (vemurafenib, previously untreated) [26] 0.32 0.22 0.69
Patients with no bone, brain, lung, or other visceral
metastases (stage IIIB–IV M1a disease)
MDX0101-20 (ipilimumab, previously treated) [23] 0.35 0.18 0.53
CA184-024 (ipilimumab, previously untreated) [24, 25] 0.31 0.18 0.60
BRIM-3 (vemurafenib, previously untreated) [26] 0.32 0.18 0.58
HR hazard ratio, ITT intent-to-treat population
Table 4 Median overall survival in months: all patients





Talimogene laherparepvec 23.3 NA
Ipilimumab 10.8 16.5
Vemurafenib 13.6 18.4
Patients with no bone, brain, lung,
or other visceral metastases
(stage IIIB–IV M1a disease)
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M1a disease), relative to all patients, can be
observed—not just at themedian ofOS but along
the entire survival curve (Figs. 2, 3, 4). This is
predictable in thatOS is expected to be longer for
patients with no visceral disease than for those
with visceral disease.
Considering the 95% confidence intervals
around the adjusted data, the talimogene
laherparepvec OS curve lies above the upper
bound of the survival data for adjusted
vemurafenib in both patient populations,
while in the case of ipilimumab the upper
bound of the survival curve can be seen to
cross with the talimogene laherparepvec
survival curve. This allows for some possibility
that ipilimumab and talimogene laherparepvec
are equivalently effective, adjusting for the
factors in the Korn algorithm.
Fig. 1 Unadjusted Kaplan–Meier OS curves for ipilimumab and vemurafenib vs. observed OS curve for talimogene
laherparepvec, all patients. OS overall survival, T-VEC talimogene laherparepvec
Fig. 2 Unadjusted and adjusted Kaplan–Meier OS curves for ipilimumab vs. observed OS curve for talimogene
laherparepvec, all patients. OS overall survival, T-VEC talimogene laherparepvec
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DISCUSSION
Treatment options for metastatic melanoma
have evolved rapidly in the past 5 years and
two key pathways, based around BRAFmutation
status, have emerged: anti-PD1 antibodies
(pembrolizumab and nivolumab) and
ipilimumab for all patients, and BRAF/MEK
inhibitor combinations for patients with
BRAF-mutant melanoma. Talimogene
laherparepvec has been approved for the
treatment of metastatic melanoma regardless
of BRAF status.
This study aimed to compare OS for
talimogene laherparepvec with ipilimumab
and vemurafenib, two of the most commonly
used treatments of patients with metastatic
melanoma. However, a conventional network
meta-analysis was not technically feasible.
Successive health technology appraisals of
treatments for patients with metastatic
melanoma have previously determined that
adjusted indirect treatment comparison with
the use of network meta-analysis is not feasible
for metastatic melanoma [14, 20, 21].
We undertook an indirect treatment
comparison using the modified Korn model, in
which patient and disease characteristics are
adjusted so that all trials reflect one reference
trial in terms of key patient characteristics—in
this case the pivotal talimogene laherparepvec
clinical trial. This approach helps to overcome
issues around generalizability and
transferability of results between and across
trials.
To our knowledge, this is the first
treatment-specific meta-analysis of
independent survival curves for metastatic
melanoma that includes recently available
therapies and that attempts to account for
significant confounders such as stage of
disease. The results from this analysis showed
that the OS with talimogene laherparepvec
appears to be at least as good as OS with
ipilimumab and vemurafenib. OS was higher
for patients treated with talimogene
laherparepvec than with ipilimumab or
vemurafenib after adjusting for differences in
patient demographic and clinical characteristics
across clinical trials; this improvement was
Fig. 3 Unadjusted and adjusted Kaplan–Meier OS curves for vemurafenib vs. observed OS curve for talimogene
laherparepvec, all patients. OS overall survival, T-VEC talimogene laherparepvec
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more pronounced in patients with no bone,
brain, lung or other visceral metastases
(stage IIIB–IV M1a disease). The adjusted OS
curve for vemurafenib was initially above, but
later went below the adjusted OS curve for
ipilimumab. This is consistent with the
observation that ipilimumab is associated with
a relatively low but durable response rate and
that vemurafenib has a high response rate but
the responses appear to be of limited duration
because of the development of treatment
resistance [22].
The findings from this analysis must be
interpreted with caution because of some
limitations. First, there is no network of RCTs
for metastatic melanoma for which both direct
and indirect comparisons exist. This would
enable preservation of treatment
randomization and consistency of indirect and
direct comparisons and would potentially allow
for meta-regression. The dearth of such an RCT
network is attributed primarily to a lack of trials;
indeed, the Cope framework [9] for assessing
the feasibility of a network meta-analysis
recommends identification of RCTs required to
resolve the issue of a lack of feasibility, and this
is in line with HTA agency assessments for
ipilimumab and vemurafenib. Second, the
algorithm used to adjust for differences in
survival, specifically the original and modified
Korn algorithms, has been used previously to
adjust for heterogeneity, but has not been
widely used in melanoma and might reflect
specific clinical trials rather than patients with
advanced melanoma generally. However, it is
the only adjustment algorithm published and
available. It was developed using a large
meta-analysis of 42 Phase 2 trials, making up
70 trial arms, and thus should be robust in its
use in melanoma. Third, the impact of
subsequent therapies on the results of OS in
talimogene laherparepvec, ipilimumab, and
vemurafenib was not specifically adjusted for.
However, subsequent therapies from those
pivotal clinical trials seemed balanced. For
example, in the OPTiM trial of talimogene
laherparepvec versus GM-CSF, the proportion
of patients receiving subsequent antimelanoma
therapy was similar between arms (43% in the
GM-CSF arm and 39% in the talimogene
Fig. 4 Adjusted Kaplan–Meier OS curves for ipilimumab
and vemurafenib vs observed OS curve for talimogene
laherparepvec, patients with no bone, brain, lung, or other
visceral metastases (stage IIIB–IV M1a disease). OS overall
survival, T-VEC talimogene laherparepvec
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laherparepvec arm); and in the CA184-024
study (ClinicalTrials.gov identifier:
NCT00324155) of ipilimumab plus dacarbazine
versus dacarbazine, therapy after disease
progression was balanced between the two
groups; 54.7% of the patients in the
ipilimumab group and 59.0% in the
dacarbazine group received subsequent
therapy. Finally, this report focuses on
comparing talimogene laherparepvec to
ipilimumab and vemurafenib because
ipilimumab and vemurafenib are the most
widely used newer agents on market.
Comparisons to other antimelanoma systemic
therapies, especially anti-PD-1 antibodies, can
be interesting and warrant further research
when the mature OS data become available for
anti-PD-1s.
This study also has several strengths. Its main
strength is that, even with the limited data at
hand, the method for adjustment and
meta-analysis allowed talimogene
laherparepvec, ipilimumab, and vemurafenib
to be compared with adjustments for this
heterogeneity. This provided for a reliable
understanding of the relative effect of
treatment on survival in a more comparable
patient population. The method permitted for
more limited inference than comparative RCTs
or network meta-analyses yet still supported the
interpretation that relative clinical benefit (i.e.,
survival) is greater for patients with earlier stages
of metastatic melanoma. The subgroup analysis
extended this finding further to patients with
stage IIIB–IV M1a disease, who are
heterogeneously in a better health state and
have a better underlying prognosis than patients
in later stages of disease with visceral metastases.
Although this study makes an important
contribution to understanding the relative
efficacy of different treatments for metastatic
melanoma, there is a clear need for active
head-to-head randomized clinical trials that
compare new treatments to each other or to
common comparators in comparable patient
populations that are generalizable to clinical
practice. This will enable stronger evidence
networks and more robust indirect treatment
comparisons, to further enhance our knowledge
of effective therapies for metastatic melanoma.
CONCLUSIONS
Even with limited data, talimogene
laherparepvec, ipilimumab, and vemurafenib
could be compared following adjustments,
thereby providing a more reliable
understanding of the relative effect of
treatment on survival in a more comparable
patient population. The results of this analysis
suggest that overall survival with talimogene
laherparepvec is at least as good as with
ipilimumab and vemurafenib and
improvement was more pronounced in
patients with no bone, brain, lung or other
visceral metastases.
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